Aster Capital Management (Difc) LTD Arcutis Biotherapeutics, Inc. Transaction History
Aster Capital Management (Difc) LTD
- $540 Billion
- Q1 2025
A detailed history of Aster Capital Management (Difc) LTD transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Aster Capital Management (Difc) LTD holds 235 shares of ARQT stock, worth $3,167. This represents 0.0% of its overall portfolio holdings.
Number of Shares
235
Previous 405
41.98%
Holding current value
$3,167
Previous $5.64 Million
42.98%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ARQT
# of Institutions
252Shares Held
126MCall Options Held
605KPut Options Held
170K-
Suvretta Capital Management, LLC New York, NY11.4MShares$154 Million7.82% of portfolio
-
Jennison Associates LLC11.4MShares$153 Million0.13% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$148 Million4.91% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$118 Million8.65% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$116 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $811M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...